Published on 30 Nov 2021 on Benzinga
Longeveron Inc. (NASDAQ: LGVN) announced Friday a clinical trial collaboration to study its lead investigational asset, Lomecel-B.
What Happened: Florida-based Longeverson said it has entered into a sponsored clinical research agreement with Japan's National Center for Geriatrics and Gerontology and the Juntendo University Hospital to study Lomcecel-B in older, frail Japanese subjects.